Please try another search
Initial data from ongoing Phase 2 part of BEXMAB trial anticipated next monthIncoming CEO, Juho Jalkanen, to accelerate discussions with US regulator to coordinate plans for...
Key highlights Latest readout of the BEXMAB study shows more responding patients and good durability of remission amongst HR HMA-failed MDS patients.4/5 of the initial Phase 1 HR...
TURKU, Finland and BOSTON, March 13, 2024 (GLOBE NEWSWIRE) -- Faron Pharmaceuticals Ltd. ("Faron" or "the Company") (AIM: FARN, First North: FARON), a clinical-stage...
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
---|---|---|---|---|---|
Moving Averages | Buy | Buy | Buy | Buy | Strong Sell |
Technical Indicators | Strong Buy | Strong Buy | Strong Buy | Strong Buy | Strong Sell |
Summary | Strong Buy | Strong Buy | Strong Buy | Strong Buy | Strong Sell |
Filter Table By:
Pattern | Timeframe | Reliability | Candles Ago | Candle Time | |
---|---|---|---|---|---|
Emerging Patterns | |||||
Mat Hold Bullish | 1H | Current | |||
Bullish Hammer | 1M | Current | |||
Completed Patterns | |||||
Downside Gap Three Methods | 1W | 1 | Apr 21, 2024 | ||
Doji Star Bearish | 1D | 1 | May 02, 2024 | ||
Engulfing Bearish | 15 | 6 | May 03, 2024 09:45AM |
Exchange | Last | Bid | Ask | Volume | Change % | Currency | Time | ||
---|---|---|---|---|---|---|---|---|---|
London | 150.00 | 140.00 | 160.00 | 8,165 | 0.00% | GBP | |||
Helsinki | 1.85 | 1.83 | 1.83 | 40,037 | +3.01% | EUR |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
---|---|---|---|---|---|---|---|---|---|
Apple | 183.36 | 187.00 | 182.66 | +10.33 | +5.97% | 153.44M | |||
NVIDIA | 887.83 | 892.81 | 870.40 | +29.66 | +3.46% | 39.02M | 03/05 | ||
Tesla | 181.14 | 184.78 | 178.43 | +1.13 | +0.63% | 74.86M | 03/05 | ||
Berkshire Hathaway B | 400.77 | 405.00 | 399.25 | +0.17 | +0.04% | 3.31M | 03/05 | ||
Microsoft | 406.66 | 407.15 | 401.86 | +8.82 | +2.22% | 16.42M | 03/05 | ||
Palantir | 23.32 | 23.53 | 22.91 | +0.77 | +3.44% | 54.49M | 03/05 | ||
Meta Platforms | 452.05 | 454.16 | 444.00 | +10.37 | +2.35% | 15.95M | 03/05 | ||
Amazon.com | 186.24 | 187.87 | 185.43 | +1.51 | +0.82% | 37.87M | 03/05 | ||
Alibaba ADR | 81.33 | 81.37 | 79.70 | +1.00 | +1.24% | 18.95M | 03/05 | ||
Alphabet A | 167.21 | 167.96 | 163.05 | +0.59 | +0.35% | 33.04M | 03/05 |
Faron Pharmaceuticals Oy operates as a clinical stage drug discovery and development company. The company’s lead product candidates are Traumakine, an investigational intravenous interferon beta-1a therapy for the prevention from cytokine release syndrome (CRS), or ischemia and hyperinflammatory conditions; and Bexmarilimab, a novel anti-Clever-1 humanized antibody that targets a subpopulation of tumor-associated macrophages and converts the highly immunosuppressive M2-like macrophages to a pro-inflammatory state to promote immune activation. The company is also developing bexmarilimab, which is in phase 2 clinical trial for indications of solid tumors; and in phase 1 clinical trial for indications of acute myeloid leukemia and myelodysplastic syndromes. In addition, it develops interferon beta-1a to prevent toxicities from CAR-T therapy in phase 2 clinical trial; and AOC3 inhibitor, which is in preclinical studies for indications of chemotherapy-induced neutropenia. Further, it develops Haematokine, an investigational AOC3 protein inhibitor that is used for regenerative medicines in hematological malignancies, as well as chemotherapy induced suppression of the bone marrow. Faron Pharmaceuticals Oy was founded in 2003 and is headquartered in Turku, Finland.
Read MoreAre you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review